未知股票 VXRT 深 沪
已收盘
--
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 --
- 最 低 --
- 昨 收 --
- 总市值 0
- 52周最高 --
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 --
- 委 比 0.00%
- 总股本 2.29亿
- 历史最高 --
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 --
- 每 手 1
- 风险率 0.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vaxart Faces Nasdaq Delisting, Moves to OTCQX
The latest update is out from Vaxart ( ($VXRT) ). Vaxart, Inc. faced a delistin...
09-20 04:35
Vaxart withdraws reverse stock split proposal
Vaxart (OTC:VXRT) announced the withdrawal of its reverse stock split proposal. Source: Press release More on Vaxart Vaxart, Inc. (VXRT) Presents at H.C. Wainwright 27th Annual Global Investment Confe...
09-19 21:19
Vaxart Withdraws Its Reverse Stock Split Proposal
Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, announced that it has
09-19 20:06
Vaxart Withdraws Proposal, Cancels Stockholder Meeting
An announcement from Vaxart ( ($VXRT) ) is now available. Vaxart, Inc. had plan...
09-19 18:27
Vaxart Appoints W. Mark Watson as Lead Independent Director
Vaxart appoints W. Mark Watson as Lead Independent Director, who brings extensive experience in finance and biotech. The company is adopting a director stock ownership policy to align board interests with stockholders. Vaxart urges shareholders to vote FOR the reverse stock split by September 18, 2025.
09-17 20:05
Vaxart's Second-Generation Oral Norovirus Vaccine Shows Up To 25-Fold Increase In Protective Fecal IgA In Phase 1 Trial
- Second-generation constructs induce robust increases in fecal IgA, which was shown to be correlated with protection against infection in the company's previous Phase 2b challenge study -SOUTH SAN FRANCISCO, Calif.,
09-11 05:03
Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate
Vaxart reported positive Phase 1 data for its second-generation oral norovirus vaccine, showing a 25-fold increase in GII.4 fecal IgA and 10-fold in GI.1 IgA over baseline with high doses, significantly outperforming first-generation constructs. These results suggest stronger intestinal immunity and potential improved efficacy, aligning with previous Phase 2b findings linking fecal IgA to protection. Vaxart aims to advance to Phase 2b trials to f...
09-10 20:54
Vaxart Adjourns Stockholder Meeting for Vote Solicitation
Vaxart ( ($VXRT) ) has shared an update. On September 5, 2025, Vaxart, Inc. adj...
09-09 05:03
Vaxart to Present at the H.C. Wainwright Global Investment Conference on September 8, 2025
The press release announces that Vaxart, Inc., a biotech company developing oral recombinant vaccines, will present at the H.C. Wainwright Global Investment Conference on September 8, 2025. The presentation will discuss the company’s proprietary oral vaccine platform, designed for needle-free administration and storage without refrigeration. Vaxart’s pipeline includes vaccines for coronavirus, norovirus, influenza, and HPV. A live webcast of the ...
09-03 12:00
Vaxart Announces Board Member Retirement
An announcement from Vaxart ( ($VXRT) ) is now available. On September 2, 2025,...
09-03 05:28
